Document Detail


Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology.
MedLine Citation:
PMID:  15955677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To estimate the prevalence of drug use disorders in the European Union and Norway. METHOD: Based on a systematic literature search and an expert survey, publications after 1990 on prevalence of drug use disorders (DUD, defined as drug dependence and drug abuse or harmful use) in EU countries and Norway were reviewed. The search included both direct estimations based on general population surveys using the DSM-IIIR, DSM-IV, or ICD-10 definitions of DUD; and indirect estimates based on other epidemiological methods, such as multiplier procedures based on treatment or legal data and capture-recapture techniques. The indirect methods did not use diagnostic criteria, but criteria based on duration and pattern of use, labelled as problematic drug use as a meaningful approximation. RESULTS: The majority of DUD as estimated from direct methods using general population surveys were cannabis use disorders, usually not included in indirect estimates. The prevalence of thus defined disorders can be as high as 3%. For disorders other than cannabis use disorders (i.e. opioid, cocaine and amphetamine use disorders), indirect estimates of prevalence were consistently higher than those based on direct estimates, and ranged between 0.3% and 0.9% in European Union countries and Norway. Men have higher prevalence rates of DUD than women, but the difference was much less pronounced in general population surveys. Younger age (18-25 years) is the age group with the highest estimates. CONCLUSION: General population surveys typically result in a serious underestimation of the prevalence of DUD other than cannabis use disorders, because many people with DUD are not reached by these surveys (hidden populations). Based on the more valid indirect estimates, it is concluded that problem drug use constitutes a relatively high burden of disease and social problems in Europe.
Authors:
Jürgen Rehm; Robin Room; Wim van den Brink; Ludwig Kraus
Related Documents :
19698347 - Six-month and lifetime prevalences of psychiatric disorders in inpatients with diabetes...
12943947 - Subthreshold psychiatric disorders in primary care: prevalence and associated character...
8450677 - Development of screeners for depressive disorders and substance disorder history.
20416027 - Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their as...
23012107 - Dermatoses in obese female schoolchildren in the al-khobar area, eastern saudi arabia.
12797587 - Model experiment of benign paroxysmal positional vertigo mechanism using the whole memb...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology     Volume:  15     ISSN:  0924-977X     ISO Abbreviation:  Eur Neuropsychopharmacol     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-07-11     Completed Date:  2005-09-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9111390     Medline TA:  Eur Neuropsychopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  389-97     Citation Subset:  IM    
Affiliation:
ISF-Addiction Research Institute, Konradstr. 32, CH 8031 Zurich, Switzerland. jtrehm@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Distribution
Data Collection
Diagnosis, Dual (Psychiatry)
Diagnostic and Statistical Manual of Mental Disorders
European Union
Female
Humans
Male
Middle Aged
Norway / epidemiology
Population Surveillance / methods*
Prevalence
Retrospective Studies
Sex Distribution
Substance Abuse Treatment Centers
Substance-Related Disorders / complications*,  epidemiology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence of dementia in the elderly in Europe.
Next Document:  Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.